We are a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies to improve surgical outcomes.
Our PLEX (Polymer-Lipid Encapsulation matriX) technology is a unique platform that is anchored in the surgical site to provide controlled and continuous delivery of medications.
Our product candidates are designed to deliver medications in the body over days to several months in a controlled manner. This allows surgeons to deliver medication right to the surgical site to improve patient outcomes in localized medical conditions such as; infection, pain, inflammation and cancer.
Our initial infection treatment targets are Surgical Site Infections (SSIs), the second most prevalent type of Healthcare Acquired Infections (HAIs). SSIs have substantial negative impact on patients’ clinical outcomes and also pose a significant healthcare system burden.
We strive to reduce overall surgical infection rates, including infections due to antibiotic-resistant bacteria which the FDA defined as being one of the world’s most pressing public health problems.
NASDAQ: PYPD
Our PLEX (Polymer-Lipid Encapsulation matriX) technology is a unique platform that is anchored in the surgical site to provide controlled and continuous delivery of medications.
Our product candidates are designed to deliver medications in the body over days to several months in a controlled manner. This allows surgeons to deliver medication right to the surgical site to improve patient outcomes in localized medical conditions such as; infection, pain, inflammation and cancer.
Our initial infection treatment targets are Surgical Site Infections (SSIs), the second most prevalent type of Healthcare Acquired Infections (HAIs). SSIs have substantial negative impact on patients’ clinical outcomes and also pose a significant healthcare system burden.
We strive to reduce overall surgical infection rates, including infections due to antibiotic-resistant bacteria which the FDA defined as being one of the world’s most pressing public health problems.
NASDAQ: PYPD
Location: Israel, Center District, Petah Tikva
Employees: 51-200
Total raised: $89.4M
Founded date: 2008
Investors 4
| Date | Name | Website |
| - | Shavit Cap... | shavitcapi... |
| - | Aurum Vent... | aurum.co.i... |
| - | Financièr... | finsj.com |
| - | Arc Ventur... | arc-vc.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 06.04.2022 | - | $15M | - |
| 04.09.2019 | Series E | $50M | - |
| 24.02.2016 | IPO | $22M | - |
| 07.01.2013 | - | $2.4M | - |
Mentions in press and media 16
| Date | Title | Description |
| 24.12.2024 | PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million | • 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; • Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application (“NDA”) for D-PLEX100 u... |
| 23.12.2024 | PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million | • 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; • Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application (“NDA”) for D-PLEX100 u... |
| 06.04.2022 | PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility | PETACH TIKVA, Israel, April 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company has entered into a secur... |
| 18.11.2021 | PolyPid : Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX100 in Abdominal Surgery - Form 6-K | PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX100 in Abdominal Surgery Company Continues to Expect that the Last Patient Will be Enrolled in the Second Quarter of 2022, Followed by Top-Line Results Two... |
| 10.11.2021 | PolyPid Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Form 6-K | PolyPid Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update Recruitment Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery Following FDA Ag... |
| 14.05.2021 | POLYPID LTD. PolyPid : Reports First Quarter 2021 Financial Results and Provides Corporate Update (Form 6-K) | PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update ● Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery ● Recruitment Rate ... |
| 12.05.2021 | POLYPID LTD. PolyPid : Reports First Quarter 2021 Financial Results and Provides Corporate Update | • Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery • Recruitment Rate in SHIELD I trial Doubled in the Last Three Weeks • Manufacturing Facility Now Fully Sca... |
| 10.02.2021 | POLYPID LTD. PolyPid : Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results | 100 Patients Enrolled into Phase 3 SHIELD I and SHIELD IITrials of D-PLEX100 in Abdominal Surgery Recently Initiated Phase 3 SHIELD II Trial Granted Breakthrough Therapy Designation from FDA for D-PLEX100 for Prevention of SSIs in Patients ... |
| 10.02.2021 | PolyPid : Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results | 100 Patients Enrolled into Phase 3 SHIELD I and SHIELD II Trials of D-PLEX100 in Abdominal Surgery Recently Initiated Phase 3 SHIELD II Trial Granted Breakthrough Therapy Designation from FDA for D-PLEX100 for Prevention of SSIs in Patients... |
| 30.06.2020 | PolyPid Ltd. Announces Closing of Initial Public Offering | PolyPid successfully completed its initial public offering on the NASDAQ, June 30th 2020. Arc Ventures first invested in the company in 2016. You can find more information about the investment here. |
Show more